Sutro Biopharma, Inc. (STRO): Price and Financial Metrics


Sutro Biopharma, Inc. (STRO)

Today's Latest Price: $11.09 USD

0.08 (0.73%)

Updated Sep 17 4:00pm

Add STRO to Watchlist
Sign Up

Overall POWR Rating


POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank


Industry Rank:

Ranked of 232 in Medical - Pharmaceuticals

See all "A" rated Strong Buy stocks

STRO Stock Summary

  • STRO's went public 1.98 years ago, making it older than just 4.03% of listed US stocks we're tracking.
  • With a price/sales ratio of 9.9, Sutro Biopharma Inc has a higher such ratio than 86.39% of stocks in our set.
  • With a year-over-year growth in debt of 89.61%, Sutro Biopharma Inc's debt growth rate surpasses 86.41% of about US stocks.
  • Stocks that are quantitatively similar to STRO, based on their financial statements, market capitalization, and price volatility, are ALBO, RMBS, CLSN, SURF, and BCRX.
  • STRO's SEC filings can be seen here. And to visit Sutro Biopharma Inc's official web site, go to www.sutrobio.com.
STRO Daily Price Range
STRO 52-Week Price Range

STRO Stock Price Chart Technical Analysis Charts


STRO Price/Volume Stats

Current price $11.09 52-week high $13.91
Prev. close $11.01 52-week low $6.00
Day low $10.78 Volume 218,864
Day high $11.33 Avg. volume 165,342
50-day MA $9.38 Dividend yield N/A
200-day MA $9.90 Market Cap 397.90M

Sutro Biopharma, Inc. (STRO) Company Bio


Sutro Biopharma, Inc. operates as clinical stage drug discovery, development, and manufacturing company. It focuses on creating protein therapeutics for cancer and autoimmune disorders through integrated cell-free protein synthesis platform, XpressCF. The company’s product candidates include STRO-001, an antibody-drug conjugate (ADC) directed against the cancer target CD74 for multiple myeloma and non-Hodgkin lymphoma; and STRO-002, an ADC directed against folate receptor-alpha for patients with ovarian and endometrial cancers. It has collaboration and license agreement with Celgene Corporation to discover and develop bispecific antibodies and/or ADCs focused primarily on the field of immuno-oncology. The company was formerly known as Fundamental Applied Biology, Inc. Sutro Biopharma, Inc. was founded in 2003 and is based in South San Francisco, California.


STRO Latest News Stream


Event/Time News Detail
Loading, please wait...

STRO Latest Social Stream


Loading social stream, please wait...

View Full STRO Social Stream

Latest STRO News From Around the Web

Below are the latest news stories about Sutro Biopharma Inc that investors may wish to consider to help them evaluate STRO as an investment opportunity.

Sutro Biopharma, Inc. (NASDAQ:STRO) Insiders Increased Their Holdings

We've lost count of how many times insiders have accumulated shares in a company that goes on to improve markedly...

Yahoo | September 4, 2020

Sutro Bio to discuss STRO-002 interim data on in ovarian cancer on Sept. 9

Sutro Biopharma (STRO) will host a conference call on Sept. 9, at 5:30 p.m. EDT to discuss updated data from ongoing Phase I dose escalation study of anti-Folate Receptor alpha (FRα) antibody-drug conjugate ((ADC)), STRO-002, in ovarian and endometrial cancer, with a data cut-off date of Aug. 31, 2020.Additionally, the company...

Seeking Alpha | September 3, 2020

Macy's, Carnival: 5 Big Stock Gainers for Thursday

Macy's, Sutro Biopharma, Carnival, John Wiley & Sons and Five Below rose in a down market Thursday.

Yahoo | September 3, 2020

The Daily Biotech Pulse: Sanofi, GSK Begin Phase 1/2 Coronavirus Vaccine Study, Fulgent Strikes COVID-19 Testing Deal, New Data From Novavax

Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 2) * Acutus Medical Inc (NASDAQ: AFIB) * Akouos Inc (NASDAQ: AKUS) * Avid Bioservices Inc (NASDAQ: CDMO) (reacted to strong quarterly results) * BioLife Solutions Inc (NASDAQ: BLFS) * Corcept Therapeutics Incorporated (NASDAQ: CORT) * Edwards Lifesciences Corp (NYSE: EW) * Evogene Ltd (NASDAQ: EVGN) * Fortress Biotech (NASDAQ: FBIO) * Generation Bio Co (NASDAQ: GBIO) * Immunovant Inc (NASDAQ: IMVT) (priced its 5.27-million-share common stock offering at $33 per share) * Inspire Medical Systems Inc (NYSE: INSP) * Intuitive Surgical, Inc. (NASDAQ: ISRG) * Silk Road Medical Inc (NASDAQ: SILK) * Shockwave Medical Inc (NASDAQ: SWAV) * Tandem Diabetes Care Inc (NASDAQ: TNDM) * TG Therapeutics Inc common stock (NASD...

Yahoo | September 3, 2020

Sutro Biopharma to Present at Two Upcoming Investor Conferences

Sutro Biopharma, Inc. (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of precise protein engineering and rational design to create next-generation oncology therapeutics, today announced that Bill Newell, Chief Executive Officer, will present at the following investor conferences in September:

Yahoo | September 3, 2020

Read More 'STRO' Stories Here

STRO Price Returns

1-mo 20.02%
3-mo 19.76%
6-mo 35.74%
1-year 3.64%
3-year N/A
5-year N/A
YTD 0.82%
2019 21.95%
2018 N/A
2017 N/A
2016 N/A
2015 N/A

Continue Researching STRO

Here are a few links from around the web to help you further your research on Sutro Biopharma Inc's stock as an investment opportunity:

Sutro Biopharma Inc (STRO) Stock Price | Nasdaq
Sutro Biopharma Inc (STRO) Stock Quote, History and News - Yahoo Finance
Sutro Biopharma Inc (STRO) Stock Price and Basic Information | MarketWatch


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 0.6011 seconds.